

Fentanyl Subcutaneous and Nasal - Palliative Care (Adult)

Contents

1.	Overview	1
2.	Presentation	1
3.	Indications	2
4.	Dose	2
4.1	Subcutaneous Fentanyl	2
4.2	Dose Conversion	3
4.3	Fentanyl Nasal Spray (transmucosal fentanyl)	4
5.	Administration	4
5.1	Diluent	4
5.2	Additional equipment.....	4
5.3	Compatibility.....	5
5.4	Administration Procedure.....	5
6.	Observation and Monitoring	5
7.	Mechanism of action.....	5
8.	Contraindications and Precautions.....	5
9.	Adverse Effects	6
10.	Drug Interactions	6
11.	References.....	6


1. Overview

Purpose

This protocol outlines the administration, prescribing and monitoring of subcutaneous and nasal fentanyl at Waitemata District Health Board.

Scope

All medical and nursing staff

 This guideline is for use in Palliative Care ONLY.

Note: Fentanyl is a very potent drug and doses are charted in **micrograms**.

Subcutaneous fentanyl is useful in palliative patients with severe renal failure, in those who require low doses of opioids and in situations where transdermal patches are contraindicated because of unstable pain.

2. Presentation

Fentanyl 100microgram/2ml and 500microgram/10ml glass ampoules

- Fentanyl injection is a clear, colourless solution

Fentanyl nasal spray 50microgram/ml (20ml) (Manufactured by WDHB Inpatient Pharmacy)

Issued by	Pharmacy & Hospital Palliative Care Team	Issued Date	February 2017	Classification	014-001-01-079
Authorised by	P&T Committee	Review Period	36 mths	Page	1 of 6

This information is correct at date of issue. Always check on Waitemata DHB Controlled Documents site that this is the most recent version.

Fentanyl Subcutaneous and Nasal - Palliative Care (Adult)

3. Indications

Licensed:

- For narcotic analgesic action of short duration during anaesthetic periods, premedication, induction and maintenance, and in the immediate post-operative period (recovery room)
- As an adjunct to general or regional anaesthesia¹

Unlicensed:

- For moderate to severe pain responsive to opioids
- For use in patients with severe renal failure^{2,3}

Unlicensed routes of administration:

- Subcutaneous
- Transmucosal

4. Dose

4.1 Subcutaneous Fentanyl

There have been numerous studies which have lead to some controversy about the pharmacokinetics, conversion factors and therefore doses of fentanyl.⁴

Note: The following doses and conversion factors are a guideline only and each patient must be assessed on an individual basis. Advice should be sought from the Palliative Care Team.

Table 1. Starting Doses if opioid naïve:

	Fentanyl Dose	Equivalent Subcut Morphine dose
Subcutaneous PRN	25 microgram every 30 minutes PRN	2.5 mg morphine subcut every 30 minutes PRN
Continuous subcutaneous infusion over 24 hours (CSCI)	50 to 100 microgram over 24 hours titrating according to symptom control	5 to 10 mg subcut morphine over 24 hours titrating according to symptom control
	Also chart 25 microgram subcut every 30 minutes PRN for breakthrough pain	

Note: Do NOT administer more than 2mL as a single stat dose subcutaneously. Stat doses larger than 2mL must be administered in two different sites.

Note: Injectable fentanyl is only available at a concentration of 50microgram/ml. It is not possible to administer more than 22mL (1100 microgram) fentanyl in the 30mL BD Luer lock syringe recommended for continuous subcutaneous infusion at WDHB.

If the fentanyl volume required for continuous subcutaneous infusion exceeds 22ml, then draw up the required fentanyl dose in a 50ml BD Luer lock syringe and add diluent to make up to 34ml total volume.

Issued by	Pharmacy & Hospital Palliative Care Team	Issued Date	February 2017	Classification	014-001-01-079
Authorised by	P&T Committee	Review Period	36 mths	Page	2 of 6

This information is correct at date of issue. Always check on Waitemata DHB Controlled Documents site that this is the most recent version.

Fentanyl Subcutaneous and Nasal - Palliative Care (Adult)

Table 2. PRN fentanyl doses for patients on a continuous subcutaneous infusion⁶

Fentanyl subcut infusion 24 hours dose (microgram)	Fentanyl subcut q30mins PRN dose (microgram)
50	25
100	25
150	25
300	50
450	75
600	100

Note: If more than three PRN doses are used in a 24 hour period the background dose may need to be adjusted.

4.2 Dose Conversion

For the purpose of this protocol, the suggested conversion ratio of subcutaneous morphine to fentanyl is 100:1^{2,5}

1mg (1000microgram) of subcut or IV morphine = 10 microgram of subcut or IV fentanyl

Table 3. Equianalgesic doses of morphine:fentanyl per 24 hours²

Morphine oral 24 hour dose (mg)	Morphine Subcut 24 hour dose (mg)	Fentanyl Subcut 24 hour dose (microgram)
10	5	50
20	10	100
30	15	150
60	30	300
90	45	450
120	60	600

Note: Provided the patient has stable pain, those using 300microgram or more over 24 hours can be switched to fentanyl patches^{7,8}

Table 4. Equianalgesic doses of fentanyl patches and continuous subcutaneous infusions

Fentanyl Patch (microgram/hr)	Subcut fentanyl (microgram/24hr)	Subcut Morphine (mg/24hr)	Oral Morphine (mg/24hr)	Subcut Oxycodone (mg/24hr)
12.5	300	30	60	30
25	600	60	120	60

Newly initiated patches may take up to 12 or more hours to reach adequate plasma levels.

Note: For patients on patches, a PRN dose of subcut fentanyl or alternative opioid must also be charted for breakthrough pain [Refer to WDHB Fentanyl Patches - Palliative Care (Adult) Protocol].

Issued by	Pharmacy & Hospital Palliative Care Team	Issued Date	February 2017	Classification	014-001-01-079
Authorised by	P&T Committee	Review Period	36 mths	Page	3 of 6

This information is correct at date of issue. Always check on Waitemata DHB Controlled Documents site that this is the most recent version.

Fentanyl Subcutaneous and Nasal - Palliative Care (Adult)

4.3 Fentanyl Nasal Spray (transmucosal fentanyl)

Several transmucosal fentanyl products are available although none are licensed or subsidised in New Zealand. The administration of injectable fentanyl via the buccal, oral or intranasal route has been widely described.^{2, 5, 9} The parenteral form of fentanyl for injection can be used as an alternative, however the preparation available in New Zealand is a low concentration, which makes the nasal spray unsuitable for patients requiring moderate or high doses of opioids for breakthrough pain.

There is no commercial preparation of fentanyl nasal spray available in New Zealand. It is compounded for each patient by pharmacy. The amount delivered in each spray depends on the spray bottle used.

For WDHB a 50microgram/ml, 20mL intranasal spray is manufactured.

Each spray delivers 0.1ml of solution = 5microgram of fentanyl.

Advice should be sought from the Palliative Care Team when prescribing fentanyl nasal spray

Nasal Spray Dose:

The dose required is patient and indication dependent

- In opioid naïve patients start with **ONE spray into each nostril and repeat after 15 minutes if inadequate response.**
- Opioid experienced patients are likely to need 25 to 50 mcg or more (5 to 10 sprays)

Doses higher than 100mcg (20 sprays) may be poorly tolerated because of the volume of drug that is required.

Storage on ward

- Fentanyl nasal spray is a controlled drug (CD). It must be stored in the controlled drug safe on the ward.
- When the patient requests a dose, write the dose out of the ward CD register in *milliliters* (1 spray = 5microgram = 0.1ml) e.g. if a patient uses 3 sprays in each nostril, write 0.6ml in the out column.
- After use, return bottle to ward CD safe until needed again (i.e. do not leave at patient's bedside).

5. Administration

5.1 Diluent

- For subcutaneous bolus administration fentanyl does not need to be diluted.
- When added to a syringe driver the recommended diluent is water for injection.

5.2 Additional equipment

- Subcutaneous Saf-T-Intima single lumen [ADM140] (*refer WDHB Policy Palliative Care- Subcutaneous Site Selection, Insertion and Monitoring of BD Saf-T-Intima Cannula*)
- Continuous subcutaneous infusion pump (Niki T34) if required

Issued by	Pharmacy & Hospital Palliative Care Team	Issued Date	February 2017	Classification	014-001-01-079
Authorised by	P&T Committee	Review Period	36 mths	Page	4 of 6

This information is correct at date of issue. Always check on Waitemata DHB Controlled Documents site that this is the most recent version.

Fentanyl Subcutaneous and Nasal - Palliative Care (Adult)

5.3 Compatibility

Compatible with:

Water for injection, 0.9% sodium chloride, metoclopramide, midazolam, haloperidol, hyoscine butylbromide, hyoscine hydrobromide, dexamethasone, ketamine, octreotide, levomepromazine, glycopyrrolate^{7,9,10}

Variable compatibility with:

Cyclizine (this combination should be avoided)^{7,10}



Do not use if the solution is cloudy or a precipitate is present.

5.4 Administration Procedure

Subcutaneous administration

- Should be injected through a BD Saf-T-Intima single lumen or directly via subcutaneous needle.
- The Saf-T-Intima should be flushed with 0.2mL of water for injection after administration of medication.
- Can be administered via a continuous subcutaneous infusion pump (Niki T34).

Intranasal administration

- Patients should sit up, hold head and bottle upright, and press nozzle.
- There is no need to breathe in/inhale the spray.
- Avoid blowing nose for 1 hour after a dose.

6. Observation and Monitoring

- Monitor for excessive drowsiness.
- Monitor for respiratory depression.

7. Mechanism of action

Fentanyl is a potent narcotic analgesic with a rapid onset and short duration of action. The principal actions are analgesia and sedation. Fentanyl is a selective μ -receptor agonist. It may cause less constipation, sedation and cognitive impairment than morphine.^{1,2}

8. Contraindications and Precautions

Contraindications

- Intolerance or hypersensitivity to fentanyl
- Myasthenia gravis
- Bronchial asthma¹

Precautions

- Respiratory impairment

Issued by	Pharmacy & Hospital Palliative Care Team	Issued Date	February 2017	Classification	014-001-01-079
Authorised by	P&T Committee	Review Period	36 mths	Page	5 of 6

This information is correct at date of issue. Always check on Waitemata DHB Controlled Documents site that this is the most recent version.

Fentanyl Subcutaneous and Nasal - Palliative Care (Adult)

- Bradycardias^{1,2}

9. Adverse Effects

Respiratory depression and apnoea	Dizziness	Hypotension
Muscle rigidity	Blurred vision	Laryngospasm
Myoclonic movements	Bradycardia	Euphoria
Nausea and vomiting	Itching	Sedation
Constipation	Confusion ^{1,3}	

10. Drug Interactions

- Monoamine oxidase inhibitors
 - Non-selective MAOIs intensify the effects of opioids which can cause anxiety, confusion and significant respiratory depression sometimes leading to coma
 - Avoid concomitant use and for 2 weeks after stopping MAOIs
- Additive effects with central nervous system depressants e.g. benzodiazepines, tricyclic antidepressants, other opioids, general anaesthetics and alcohol
- Use with SSRIs may increase the risk of serotonin syndrome¹

11. References

1	Medsafe Website - Fentanyl Datasheet. http://www.medsafe.govt.nz/profs/Datasheet/f/FentanylSolforinj.pdf [cited 4/8/2016]
2	Twycross R, Wilcock A, Howard P (eds). Palliative Care Formulary Online edition – Principles of Use of Analgesics, Opioid Dose Conversion Ratios, Fentanyl monographs and Appendix 3 Compatibility charts. http://www.palliativedrugs.com [cited 4/8/2016]
3	New Zealand Formulary online, release 50-1 August 2016 – Fentanyl monograph. http://nzf.org.nz [cited 4/8/2016]
4	Sweetman S (ed) Martindale. The Complete Drug Reference. 37 th Edition. Pharmaceutical Press 2011. London, UK.
5	Watanabe S, Pereira J, Hanson J, and Bruera E. Fentanyl by Continuous Infusion for the Managements of Cancer Pain: A Retrospective Study. Journal of Pain and Symptom Management. Volume 16. No 5. November 1998. 323-326.
6	Adapted from Twycross R, Wilcock A, Howard P (eds). Palliative Care Formulary Online edition – Fentanyl monograph http://www.palliativedrugs.com [cited 4/8/2016]
7	Back I et al (eds). Palliative Medicine Handbook Online edition. BPM Books, Cardiff, UK. http://book.pallcare.info [cited 4/8/2016]
8	WDHB Fentanyl Patches – Palliative Care Protocol
9	Dickman A, Schneider J. The Syringe Driver – Continuous subcutaneous infusions in palliative care. 3rd ed. New York: Oxford university press; 2011.
10	MacLeod R, Vella-Brincat J, MacLeod A, The Palliative Care Handbook 8th edition 2016, Soar Printers. http://www.hospice.org.nz/resources/palliative-care-handbook [cited 4/8/2016]

Issued by	Pharmacy & Hospital Palliative Care Team	Issued Date	February 2017	Classification	014-001-01-079
Authorised by	P&T Committee	Review Period	36 mths	Page	6 of 6

This information is correct at date of issue. Always check on Waitemata DHB Controlled Documents site that this is the most recent version.